Together these data confirm that circulating FSHD biomarkers reflect muscle pathogenesis, and suggest inflammatory S100A8/TLR4 signaling plays a role in pediatric-onset FSHD as well. This evidence concerns the gene TLR4 and facioscapulohumeral muscular dystrophy.